Fred Alger Management, LLC Castle Biosciences Inc Transaction History

Fred Alger Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$16.0 - $45.99 $830,128 - $2.39 Million	-51,883 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$33.17 - $46.98 $1.72 Million - $2.44 Million	51,883 New	51,883 $2.33 Million
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $3.14 Million - $5.43 Million	-80,293 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $4.83 Million - $6.23 Million	80,293 New	80,293 $5.34 Million
Q1 2021 May 17, 2021	SELL	$58.92 - $97.33 $1.29 Million - $2.13 Million	-21,839 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$43.6 - $73.05 $499,656 - $837,153	11,460 Added 110.42%	21,839 $1.47 Million
Q3 2020 Nov 13, 2020	SELL	$38.47 - $52.03 $216,239 - $292,460	-5,621 Reduced 35.13%	10,379 $534,000
Q1 2020 May 15, 2020	SELL	$23.08 - $35.53 $138,480 - $213,180	-6,000 Reduced 27.27%	16,000 $477,000
Q4 2019 Feb 14, 2020	BUY	$15.74 - $35.04 $31,480 - $70,080	2,000 Added 10.0%	22,000 $756,000
Q3 2019 Nov 14, 2019	BUY	$18.09 - $27.92 $361,800 - $558,400	20,000 New	20,000 $362,000

201

24.5M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $724M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.